Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2022 Filed Aug 12, 2022 16:11 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,500 | $57.76 | $144,400.00 |
DisclosureSEC source: 0001127602-22-020860 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 21:24 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,545 | $240.72 | $371,912.40 |
DisclosureSEC source: 0001127602-22-020493 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,286 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 22, 2022 Filed Jul 26, 2022 15:59 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,500 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-019773 · form4.xml · derivative · entry 7 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: ResMed Common Stock · 2,500 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| July 22, 2022 Filed Jul 26, 2022 15:59 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,500 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-019773 · form4.xml · derivative · entry 6 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: ResMed Common Stock · 2,500 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| July 22, 2022 Filed Jul 26, 2022 15:59 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,500 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-019773 · form4.xml · derivative · entry 5 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: ResMed Common Stock · 2,500 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| July 22, 2022 Filed Jul 26, 2022 15:59 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 7,500 | $235.00 | $1,762,500.00 |
DisclosureSEC source: 0001127602-22-019773 · form4.xml · nonDerivative · entry 4 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,426 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 71.359 shares of ResMed stock purchased on April 29, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| July 22, 2022 Filed Jul 26, 2022 15:59 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,500 | $57.76 | $144,400.00 |
DisclosureSEC source: 0001127602-22-019773 · form4.xml · nonDerivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 22, 2022 Filed Jul 26, 2022 15:59 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,500 | $57.76 | $144,400.00 |
DisclosureSEC source: 0001127602-22-019773 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 22, 2022 Filed Jul 26, 2022 15:59 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,500 | $57.76 | $144,400.00 |
DisclosureSEC source: 0001127602-22-019773 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 17:31 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-019401 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,265 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 17:31 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $224.94 | $1,276,517.48 |
DisclosureSEC source: 0001127602-22-019401 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,260 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $222.45 to $225.95. The price reported above reflects the weighted average sale price. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 17:31 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-019401 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 22:31 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,545 | $212.33 | $328,049.85 |
DisclosureSEC source: 0001127602-22-019009 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,831 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 19:47 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-017597 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,940 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 19:47 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $202.54 | $1,149,409.96 |
DisclosureSEC source: 0001127602-22-017597 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,260 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $199.47 to $206.01. The price reported above reflects the weighted average sale price. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 19:47 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-017597 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 12:35 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,545 | $209.44 | $323,584.80 |
DisclosureSEC source: 0001127602-22-016949 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,376 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 62.7151 shares of ResMed stock purchased on April 29, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 16, 2022 Filed May 17, 2022 17:20 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-014711 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,615 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| May 16, 2022 Filed May 17, 2022 17:20 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $196.61 | $1,115,744.73 |
DisclosureSEC source: 0001127602-22-014711 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,260 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $195.10 to $198.04. The price reported above reflects the weighted average sale price. F3 · balance_after: Includes 30.8872 shares of ResMed stock purchased on April 29, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 16, 2022 Filed May 17, 2022 17:20 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-014711 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:03 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,545 | $200.00 | $309,000.00 |
DisclosureSEC source: 0001127602-22-013220 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,858 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 00:34 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-012221 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,290 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 00:34 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $232.41 | $1,318,946.61 |
DisclosureSEC source: 0001127602-22-012221 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,229 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $231.15 to $234.52. The price reported above reflects the weighted average sale price. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 00:34 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-012221 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 18:09 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-22-012108 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,098 Underlying: ResMed Common Stock · 8,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 18:09 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 8,000 | $233.29 | $1,866,320.00 |
DisclosureSEC source: 0001127602-22-012108 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,175 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 18:09 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock | 8,000 | $58.24 | $465,920.00 |
DisclosureSEC source: 0001127602-22-012108 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 11, 2022 Filed Apr 12, 2022 21:54 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,500 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-011914 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: ResMed Common Stock · 2,500 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 11, 2022 Filed Apr 12, 2022 21:54 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $247.00 | $617,500.00 |
DisclosureSEC source: 0001127602-22-011914 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,354 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 11, 2022 Filed Apr 12, 2022 21:54 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,500 | $57.76 | $144,400.00 |
DisclosureSEC source: 0001127602-22-011914 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 20:33 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,544 | $246.60 | $380,750.40 |
DisclosureSEC source: 0001127602-22-011560 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,403 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 19:24 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-009461 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,965 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 19:24 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $242.37 | $1,375,421.94 |
DisclosureSEC source: 0001127602-22-009461 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,229 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $238.87 to $244.98. The price reported above reflects the weighted average sale price. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 19:24 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-009461 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 18:51 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-22-009455 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,098 Underlying: ResMed Common Stock · 8,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 18:51 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 8,000 | $238.07 | $1,904,560.00 |
DisclosureSEC source: 0001127602-22-009455 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,175 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 18:51 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock | 8,000 | $58.24 | $465,920.00 |
DisclosureSEC source: 0001127602-22-009455 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 16:14 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,500 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-009063 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: ResMed Common Stock · 2,500 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 16:14 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $241.29 | $603,225.00 |
DisclosureSEC source: 0001127602-22-009063 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,354 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 16:14 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,500 | $57.76 | $144,400.00 |
DisclosureSEC source: 0001127602-22-009063 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 19:04 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,544 | $250.62 | $386,957.28 |
DisclosureSEC source: 0001127602-22-008215 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,947 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 23:31 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-005395 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,640 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 23:31 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $234.06 | $1,328,270.64 |
DisclosureSEC source: 0001127602-22-005395 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,229 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $232.67 to $235.27. The price reported above reflects the weighted average sale price. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 23:31 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-005395 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:08 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock Options · Derivative | 8,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-22-005282 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,098 Underlying: ResMed Common Stock · 8,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:08 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 8,000 | $235.81 | $1,886,480.00 |
DisclosureSEC source: 0001127602-22-005282 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,175 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 21:08 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock | 8,000 | $58.24 | $465,920.00 |
DisclosureSEC source: 0001127602-22-005282 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 17:59 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,500 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-004725 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: ResMed Common Stock · 2,500 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 17:59 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $241.86 | $604,650.00 |
DisclosureSEC source: 0001127602-22-004725 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,354 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 17:59 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock | 2,500 | $57.76 | $144,400.00 |
DisclosureSEC source: 0001127602-22-004725 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.